Cargando…

Development and Internal Validation of a Novel Model to Identify Inflammatory Biomarkers of a Response to Escitalopram in Patients With Major Depressive Disorder

Objective: The aim of our study was to identify immune- and inflammation-related factors with clinical utility to predict the clinical efficacy of treatment for depression. Study Design: This was a follow-up study. Participants who met the entry criteria were administered with escitalopram (5–10 mg/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jingjing, Zhou, Jia, Sun, Zuoli, Feng, Lei, Zhu, Xuequan, Yang, Jian, Wang, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172985/ https://www.ncbi.nlm.nih.gov/pubmed/34093252 http://dx.doi.org/10.3389/fpsyt.2021.593710

Ejemplares similares

Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
por: Sun, Zuoli, et al.
Publicado: (2023)

Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial
por: Zhou, Jingjing, et al.
Publicado: (2019)

Label-Free Liquid Chromatography–Mass Spectrometry Proteomic Analysis of the Urinary Proteome for Measuring the Escitalopram Treatment Response From Major Depressive Disorder
por: Huan, Yuhang, et al.
Publicado: (2021)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Identifying circulating biomarkers for major depressive disorder
por: Zhang, En, et al.
Publicado: (2023)

Correlation Between Word Frequency and 17 Items of Hamilton Scale in Major Depressive Disorder
por: Han, Jiali, et al.
Publicado: (2022)

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine
por: Li, Zhe, et al.
Publicado: (2023)

Colchicine-Resistant Familial Mediterranean Fever With Depressive State Successfully Treated With Escitalopram
por: Toshida, Masamitsu, et al.
Publicado: (2021)

Reduced Plasma Levels of α-Klotho and Their Correlation With Klotho Polymorphisms in Elderly Patients With Major Depressive Disorders
por: Gao, Xiang, et al.
Publicado: (2021)

Metoprolol, N-Acetylcysteine, and Escitalopram Prevents Chronic Unpredictable Mild Stress-Induced Depression by Inhibition of Endoplasmic Reticulum Stress
por: Yang, Lixia, et al.
Publicado: (2018)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Efficacy and Safety of Escitalopram Oral Drops to Treat Major Depressive Disorder and Generalized Anxiety Disorder in Adolescent, Adult and Geriatric Patients: A Prospective Multicenter Observational Study in Pakistan
por: Afridi, Muhammad Iqbal, et al.
Publicado: (2020)

Regional White Matter Integrity Predicts Treatment Response to Escitalopram and Memantine in Geriatric Depression: A Pilot Study
por: Krause-Sorio, Beatrix, et al.
Publicado: (2020)

Effects of escitalopram therapy on resting-state functional connectivity of subsystems of the default mode network in unmedicated patients with major depressive disorder
por: Cui, Jian, et al.
Publicado: (2021)

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder
por: Zhang, Shudong, et al.
Publicado: (2023)

The core inflammatory factors in patients with major depressive disorder: a network analysis
por: Zeng, Yexian, et al.
Publicado: (2023)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

Efficacy of an Internet-Based Intervention for Subclinical Depression (MoodBox) in China: Study Protocol for a Randomized Controlled Trial
por: Chen, Xu, et al.
Publicado: (2021)

L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder
por: Nie, Li-Juan, et al.
Publicado: (2021)

Low-quality of patient-reported outcome reporting in randomized clinical trials of major depressive disorder—a meta-epidemiological review
por: Zhou, Jia, et al.
Publicado: (2023)

Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder
por: Young, Juan Joseph, et al.
Publicado: (2016)

Metabolic and Microbiota Measures as Peripheral Biomarkers in Major Depressive Disorder
por: Horne, Rachael, et al.
Publicado: (2018)

Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial
por: Cigognini, Marco Aurélio, et al.
Publicado: (2022)

Identification of Sex-Specific Plasma Biomarkers Using Metabolomics for Major Depressive Disorder in Children and Adolescents
por: Jiang, Yuanliang, et al.
Publicado: (2022)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

Differential Effects of Single-Dose Escitalopram on Cognitive and Affective Interference during Stroop Task
por: Rahm, Christoffer, et al.
Publicado: (2014)

A Systematic Review and Individual Patient Data Network Analysis of the Residual Symptom Structure Following Cognitive-Behavioral Therapy and Escitalopram, Mirtazapine and Venlafaxine for Depression
por: Whiston, Aoife, et al.
Publicado: (2022)

M2-AChR Mediates Rapid Antidepressant Effects of Scopolamine Through Activating the mTORC1-BDNF Signaling Pathway in the Medial Prefrontal Cortex
por: Liu, Shuang, et al.
Publicado: (2021)

Search for serum biomarkers in patients with bipolar disorder and major depressive disorder using metabolome analysis
por: Sun, Xiao-Li, et al.
Publicado: (2023)

Trends in prescription therapy for adolescents with depression in nine major areas of China during 2017–2021
por: Wang, Li, et al.
Publicado: (2023)

Potential value of serum brain-derived neurotrophic factor, vascular endothelial growth factor, and S100B for identifying major depressive disorder in knee osteoarthritis patients
por: Zhang, Peng, et al.
Publicado: (2022)

Common Brain Networks Between Major Depressive-Disorder Diagnosis and Symptoms of Depression That Are Validated for Independent Cohorts
por: Yamashita, Ayumu, et al.
Publicado: (2021)

Alterations of Plasma Lipids in Adult Women With Major Depressive Disorder and Bipolar Depression
por: Zhang, Ting, et al.
Publicado: (2022)

The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Zhou, Jingjing, et al.
Publicado: (2020)

Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder
por: Song, Ruize, et al.
Publicado: (2021)

Problem Solving Therapy Improves Effortful Cognition in Major Depression
por: Jiang, Chenguang, et al.
Publicado: (2021)

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder
por: Martens, Marieke A. G., et al.
Publicado: (2021)

Transcutaneous Electrical Cranial-Auricular Acupoint Stimulation vs. Escitalopram for Patients With Mild-to-Moderate Depression (TECAS): Study Design for a Randomized Controlled, Non-inferiority Trial
por: Yang, Sichang, et al.
Publicado: (2022)

Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder
por: Rahimian, Reza, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hijip4bkt9cg7bfquvlcr9hktd